India Grants First Marketing Approval for Dengue Vaccine QDENGA

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has granted marketing authorisation for the country's first dengue vaccine. The nod was given for QDENGA (TAK-003), a recombinant live attenuated vaccine developed by Japanese pharmaceutical firm Takeda.

The vaccine is approved for use in individuals aged 4 to 60 years. This makes it the first such preventive measure against dengue to be cleared for the Indian market.

Dengue Burden in India

Dengue is a major public health challenge in India. The mosquito-borne viral infection causes hundreds of thousands of cases each year, with outbreaks occurring across states during the monsoon season.

Seasonal surges often overwhelm healthcare facilities. Severe dengue can lead to complications like plasma leakage, fluid accumulation, respiratory distress, and organ impairment. A vaccine has long been seen as a critical tool to bring the disease under control.

The QDENGA Vaccine

QDENGA, also known as TAK-003, is a live attenuated vaccine. It targets all four serotypes of the dengue virus. Clinical trials have shown it to be effective in reducing the incidence of dengue and hospitalisation due to the disease.

The vaccine has already been approved in several countries across Europe, Latin America, and Asia. Its authorisation in India comes after a thorough review of safety and efficacy data by the Subject Expert Committee of the CDSCO.

The drug regulator's approval is for marketing the vaccine in the country. It is not part of the national immunisation programme at this stage.

Import and Availability

QDENGA is manufactured in Japan by Takeda. The company will now import and distribute the vaccine in India through its local arm or partners.

Pricing and commercial launch timelines have not been announced yet. The vaccine is expected to be available through private markets initially. Its inclusion in public health programmes will depend on further recommendations from expert panels and cost-effectiveness studies.

The approval follows a recommendation from the Subject Expert Committee in June 2025, which had reviewed the vaccine's clinical data and proposed conditions for its use.

What This Means for Public Health

Public health experts have welcomed the move. They say a safe and effective vaccine can reduce the disease burden significantly, especially in endemic areas. However, they caution that vaccination alone will not eliminate dengue.

Vector control measures, public awareness, and early diagnosis remain essential. The vaccine is not a substitute for these efforts but an additional layer of protection.

Officials have not confirmed whether the vaccine will be recommended for all age groups or targeted at specific high-risk populations. Post-marketing surveillance will be critical to monitor real-world effectiveness and safety.

The approval is a milestone for India's fight against dengue. Attention now shifts to how quickly the vaccine reaches those who need it most, and whether it will eventually become part of the country's routine immunisation schedule.